IONSIonis Pharmaceuticals, Inc.Finished
GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Macular Degeneration · Geographic Atrophy
18Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Apr 2024, none posted yet
Counts until it's fixed
- +7.8
2 insiders sold shares within a month
Since Oct 16, 2026 · was worth 10, fading over time
Worry score18
Score over time
- Stage
- Phase 2
- Patients
- 332 (final count)
- Started
- Mar 4, 2019
- Main results expected
- Apr 18, 2024
- Fully finished
- Jun 12, 2024
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Rate of Change from Baseline in the Geographic Atrophy (GA) Area at Week 49, as Assessed by Retinal Imaging
Measured over: Week 49
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-04-18, no fading
- insider_selling_cluster: base 10, now 7.8, since 2026-10-16, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03815825 · record last updated 2025-03-07 · checked 2026-11-09 06:30 UTC